COMMUNIQUÉS West-GlobeNewswire

-
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
19/12/2018 -
NexTech Launches Ecommerce AR Solution for Shopify, Magento & WordPress -- CFN Media
19/12/2018 -
Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million
19/12/2018 -
Tabula Rasa HealthCare Appoints Kevin Boesen as Chief Sales Officer
19/12/2018 -
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
19/12/2018 -
Evolus Added to NASDAQ Biotechnology Index
19/12/2018 -
Spectral to Attend the 37th Annual J.P. Morgan Healthcare Conference
19/12/2018 -
Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments
19/12/2018 -
Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa
19/12/2018 -
AMAG Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
19/12/2018 -
Johnson & Johnson's Biosense Webster’s MaryAnn Edzards Joins BioSig
19/12/2018 -
resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences
19/12/2018 -
RTI Donor Services and Versiti Celebrate the Gift of Tissue Donation with Donate Life Float in 2019 Rose Parade®
19/12/2018 -
Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
19/12/2018 -
Immunomedics To Present at the 37th Annual J.P. Morgan Healthcare Conference
19/12/2018 -
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
19/12/2018 -
CardioDx Presents Comparative Effectiveness Claims Analysis Highlighting the Clinical Value of the Corus® CAD Precision Medicine Blood Test in Elderly Patients at the Gerontological Society of America 2018 Annual Meeting
19/12/2018 -
Avalon GloboCare to Ring the Nasdaq Stock Market Closing Bell on January 7, 2019 at 4:00 PM Eastern
19/12/2018 -
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
19/12/2018
Pages